These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25544659)

  • 21. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV vaccination: too soon for 2 doses?
    Kahn JA; Bernstein DI
    JAMA; 2013 May; 309(17):1832-4. PubMed ID: 23632729
    [No Abstract]   [Full Text] [Related]  

  • 25. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPV and cervical cancer: screening or vaccination?
    Bosch FX; Castellsagué X; de Sanjosé S
    Br J Cancer; 2008 Jan; 98(1):15-21. PubMed ID: 18182975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NIH lab helps get vaccine from bench to bedside.
    Traynor K
    Am J Health Syst Pharm; 2007 Mar; 64(5):452. PubMed ID: 17322152
    [No Abstract]   [Full Text] [Related]  

  • 30. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
    Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
    Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of cervical cancer through vaccination of adolescents.
    Pichichero ME
    Clin Pediatr (Phila); 2006 Jun; 45(5):393-8. PubMed ID: 16891270
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevention of cervical cancer: where immunology meets diagnostics.
    Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
    Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.
    Frederick PJ; Huh WK;
    Expert Rev Anticancer Ther; 2008 May; 8(5):701-5. PubMed ID: 18471043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for cervical cancer: controversy and contention or thoughtful analysis.
    Frable WJ
    Cancer; 2007 Jun; 111(3):143-4. PubMed ID: 17487849
    [No Abstract]   [Full Text] [Related]  

  • 37. Vaccination protects against invasive HPV-associated cancers.
    Luostarinen T; Apter D; Dillner J; Eriksson T; Harjula K; Natunen K; Paavonen J; Pukkala E; Lehtinen M
    Int J Cancer; 2018 May; 142(10):2186-2187. PubMed ID: 29280138
    [No Abstract]   [Full Text] [Related]  

  • 38. Prospects for cervical cancer prevention by human papillomavirus vaccination.
    Schiller JT; Lowy DR
    Cancer Res; 2006 Nov; 66(21):10229-32. PubMed ID: 17079437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening: Testing times.
    Humphries C
    Nature; 2012 Aug; 488(7413):S8-9. PubMed ID: 22932440
    [No Abstract]   [Full Text] [Related]  

  • 40. Gynaecological cancer: HPV vaccine: is age just a number?
    Stone L
    Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.